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Hepatitis B virus (HBV) infects the liver and uses its cell host for gene expression and propagation.
Therefore, targeting host factors essential for HBV gene expression is a potential anti-viral strategy.
Here we show that treating HBV expressing cells with the natural phenolic compound curcumin
inhibits HBV gene expression and replication. This inhibition is mediated via down-regulation of
PGC-1a, a starvation-induced protein that initiates the gluconeogenesis cascade and that has been
shown to robustly coactivate HBV transcription. We suggest curcumin as a host targeted therapy
for HBV infection that may complement current virus-speciﬁc therapies.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis B virus (HBV) is a small DNA virus infecting the liver
almost exclusively [1]. Chronic infection with HBV might lead to
severe liver pathologies including chronic hepatitis, cirrhosis and
a fatal cancer designated hepatocellular carcinoma [2]. HBV-
induced liver disease is directly correlated with the level of viral
activity, making an efﬁcient anti-viral therapy an extremely impor-
tant component in the management and surveillance of chronically
infected patients [3]. The current anti-HBV drugs of choice are
members of the nucleotide/nucleoside analogues, which suppress
HBV through inhibition of its polymerase/reverse-transcriptase
activity. The virus speciﬁcity of these efﬁcient agents is a double
edge sword, since although almost devoted of unwanted adverse
effects, the prolonged use of polymerase inhibitors carry a substan-
tial risk for emerging of escape mutants and a potential ﬂare-up of
the disease. Indeed, the inability of the reverse-transcriptasechemical Societies. Published by E
xisome proliferator-activated
rface antigen; cccDNA, cova-
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lomai).inhibitors to totally eliminate the HBV cccDNA pool usually neces-
sitates a prolonged or life-long therapy [4]. Therefore, an ideal
therapy should be the combination of both virus-speciﬁc and
host-directed therapies.
Recently, we have shown that the metabolic regulator PGC-1a,
a coactivator of key gluconeogenesis genes [5,6], robustly coacti-
vates the transcription of HBV through the nuclear receptor HNF4a
[7] and the forkhead transcription factor FOXO1 [8]. Physiologi-
cally, we have shown that under starvation when PGC-1a is in-
duced HBV expression is dramatically enhanced, an effect that is
largely reversible upon re-feeding. Notably, knocking-down PGC-
1a under both fed and starvation states results in a signiﬁcant
down-regulation of HBV expression [7]. Therefore, as a ‘‘metabolo-
virus” that is largely dependent on the metabolic regulator PGC-1a
for its gene expression [9], HBV is extremely susceptible to any
manipulation in PGC-1a level. Thus, targeting PGC-1a is a potential
anti-HBV strategy.
The natural phenolic compound curcumin has been shown to
have anti-inﬂammatory, anti-oxidant and anti-proliferative effects
on cells, thereby profoundly affecting their metabolism and prolif-
erative potential [10,11]. Furthermore, curcumin has been shown
to have an inhibitory effect against a variety of organisms such
as bacteria, fungi and viruses, including HBV, HCV and HIV
[12–15]. The mechanism by which curcuminmediates its anti-viral
activity differs from virus to virus and may involve a directlsevier B.V. All rights reserved.
2486 M. Mouler Rechtman et al. / FEBS Letters 584 (2010) 2485–2490inhibition of the viral replication machinery, such as in the case of
HIV [14], or inhibition of a cellular signaling pathway essential for
viral replication, such as in the case of HCV [13]. Interestingly, in
addition to its ability to inhibit cell signaling at multiple levels
and to affect cellular enzymes, curcumin has been shown to specif-
ically target cellular proteins and promote their degradation, as
was recently shown with p53 [16]. This degradation is mediated
through a unique ‘‘degradation by default” pathway common to
short-lived regulatory proteins that are intrinsically disordered in
their structure [17,18]. As a short-lived regulatory protein [19]
with a predicted disordered structure (unpublished data) we spec-
ulated that the HBV coactivator PGC-1a is susceptible to curcumin-
induced protein degradation.
Therefore, we examined the potential inhibitory effect of curcu-
min on HBV expression and replication and further investigated
whether curcumin-induced PGC-1a protein degradation is mecha-
nistically involved in HBV inhibition.Fig. 1. Curcumin suppresses both HBV and PGC-1a proteins. (A) HepG2215 cells
were either left untreated or alternatively treated with increasing amounts (100
and 150 lM) of curcumin for 4 h each day for three consecutive days after which all
cells were left untreated for additional 2 days. Medium from each day was collected
and analyzed for HBsAg level. HBsAg level in medium of untreated cells from each
of the ﬁve experiment days was considered as 100% HBsAg level. The results are an
average ± S.D of three independent experiments, each performed in triplicates. (B)
HepG2215 cells were either left untreated or alternatively treated with increasing
amounts (100 and 150 lM) of curcumin for 4 h, after which cells were harvested,
protein extracted and analyzed by aWestern-blot. The relative intensities (RI) of the
bands after normalization to actin levels are shown below the corresponding
panels.2. Materials and methods
2.1. Cell culture and treatments
HepG2, HepG2215 and HEK293 cells were maintained in Dul-
becco’s modiﬁed Eagle’s minimal essential medium as previously
described [20]. Cells were seeded at about 60% conﬂuence 18–
24 h prior to transfection, which was carried out by the CaHPO4
method as previously described [20]. For hormonal treatments
cells were maintained in serum-free DMEM medium and subse-
quently were treated with 10–100 lM of forskolin (Sigma, cata-
logue number F6886) as previously described [7] with or without
50–150 lM of curcumin (dissolved in EtOH) for 4 h as previously
described [16]. Cyclohexamide (60 lM, Sigma catalogue number
01810) was added to cells for up to 70 min for translation inhibi-
tion experiments. Lamivudine (1 mM, GlaxoSmithKline, Australia)
was added to cells for 4 h for viral inhibition. Cell viability was as-
sessed by trypan blue exclusion. Brieﬂy, cells were counted in a
hemocytometer following 1–2 min incubation with 1:1 0.4% try-
pan blue. Counted number of unstained cells represents the per-
centage of viable cells.
2.2. Plasmid constructs
For 1.3 HBV construction, an over-length HBV genome (adw
strain) of 4195 bp was produced, harboring a 50 terminus of the un-
ique EcoRV site (nt 1043, considering EcoRI unique site in the ori-
ginal 3.2 kb HBV construct as nt number 1) and a 30 terminus of the
unique Taq1 site (nt 2017). This EcoRV-TaqI fragment was inserted
between the SmaI-AccI unique sites of a pGEM-3Z plasmid, respec-
tively. The 1.3 HBV-Luc plasmid has been previously described
[7]. The pSG5-PGC-1a plasmid is a gift from B.M Spiegelman
(Dana-Farber, Harvard).
2.3. Protein analysis
Proteins were extracted from cells by RIPA extraction according
to published protocols, and subsequently fractioned on 7% (for
pgc1) or 12.5% (for HBV Core) SDS–PAGE. For western blot analysis,
gels were electro-blotted to a nitrocellulose membrane, which was
later soaked for 1 h on a blocking solution [Phosphate buffer saline
(PBS) containing 5% non-fat milk and 0.01%v/v tween-20 (Sigma)],
and incubated for 1–2 h at RT in the presence of either one of the
following antibodies: monoclonal mouse anti HBcAg (clone 22, di-
luted 1:5000), mouse anti pgc1 antibody (Calbiochem #ST1202, di-
luted 1:2000), mouse anti HA antibody (Covance #MMS-101R,
diluted 1:2000), and mouse anti actin antibody (Santa Cruzsc47778, diluted 1:5000). After incubation, the membrane was
washed three times, and Goat anti mouse conjugated with horse
radish peroxidase (Jackson #115-035-062, diluted 1:5000) was
added and incubation was allowed to proceed for an additional
1 h. Antibody-antigen complexes were visualized by ECL on an
X-ray ﬁlm.
2.4. ELISA analysis
Medium from HBV stably-transfected HepG2215 cells was col-
lected and analyzed for HBsAg level using the ADVIA Centaur ma-
chine (Bayer HealthCare LLC, Tarrytown, NY) with HBsAg reagent
kit (ref#03393362).
2.5. RNA analysis
RNA was extracted from cells using EZ-RNA isolation kit (Bio-
logical Industries, Israel, Beit Haemek) according to the manufac-
turer’s protocol. After treatment with RNase-free DNaseI
(Promega #M610A), RNA was subjected to quantitative RT-PCR
analysis using the following primers:
HBV FW: TGTGGATTCGCACTCCTCCAGC;HBV Rev: TGCGAGGC-
GAGGGAGTTCTT;
HPRT1 (h/m) FW: TGACACTGGCAAAACAATGCA;HPRT1 (h/m)
Rev: GGTCCTTTTCACCAGCAAGCT.
M. Mouler Rechtman et al. / FEBS Letters 584 (2010) 2485–2490 24873. Results and discussion
3.1. Curcumin inhibits HBV expression and replication in stably-
transfected hepatoma cells
We ﬁrst investigated the inhibitory effect of curcumin on HBV
in a stably-transfected HepG2215 cell line that continuously ex-
presses HBV [21] and that more authentically simulates a HBV-in-
fected liver. We quantiﬁed the secreted HBV surface antigen
(HBsAg) level from the medium of HepG2215 cells as a marker
for HBV replication. Cells were treated for 4 h each day for three
consecutive days with various concentrations of curcumin. At the
end of each daily treatment medium was collected, analyzed for
HBsAg level and was subsequently replaced by fresh medium. Cell
viability was assessed by the trypan blue exclusion method to rule-
out a non-speciﬁc toxic effect. As shown in Fig. 1A, whereas no
change in the secreted HBsAg level was detected upon curcumin
treatment at the end of the ﬁrst day of treatment, a signiﬁcant
dose-dependent reduction of up to 65% from baseline in HBsAg
levels was detected in curcumin-treated cells at the end of the sec-
ond and the third days of treatment. Notably, one day after treat-
ment cessation HBsAg levels in curcumin-pre-treated cellsFig. 2. Curcumin suppresses HBV expression through inhibition of PGC-1a. (A) (Upper
(Lower panel) HepG2 cells were transfected with the indicated plasmids. Two days after
harvested and analyzed for luciferase activity. Results were normalized to b Gal activity
triplicates (*P = 0.03, calculated by Student t-test). (B) HepG2 cells were transfected with t
performed as indicated, after which cells were harvested, RNA was extracted and subjecte
(C) The same experimental procedure as in Bwas performed, this time cells were harvested
days later cells were treated as indicated (Forsk 10 lM, Curc 50 lM for 4 h) after whichcontinued to decrease and reached their nadir level (up to 73%
reduction in HBsAg level as compared to non-treated cells). How-
ever, on the second post-treatment day an increase in HBsAg levels
of 10% was detected (Fig. 1A), suggesting that the anti-HBV effect
in HepG2215 cells is curcumin-dependent.
Compatible with these results, protein analysis of curcumin-
treated HepG2215 cells revealed a signiﬁcant dose-dependent de-
crease of up to 45% from baseline in HBV Core protein level
(Fig. 1B). Interestingly, analysis of PGC-1a protein in those cells re-
vealed a substantial level of PGC-1a at baseline that steadily de-
creased with curcumin treatment paralleling the decrease in HBV
Core protein level (Fig. 1B).
Overall, these results strongly suggest that curcumin inhibits
HBV and that this inhibition correlates with a signiﬁcant decrease
in PGC-1a protein level.
3.2. Curcumin treatment results in suppression of HBV expression in a
PGC-1a dependent manner
We have previously shown that PGC-1a strongly coactivates
HBV transcription and that during physiological conditions
in which hepatic PGC-1a is induced, HBV gene expression ispanel) a schematic presentation of the HBV-Luc construct used in this experiment.
transfection cells were treated with curcumin (50 lM for 4 h) after which cells were
. The results are an average of three independent experiments, each performed in
he indicated plasmids. Two days later treatment with curcumin (50 lM for 4 h) was
d to semi-quantitative (upper panel) and quantitative (lower panel) RT-PCR analysis.
for protein analysis as indicated. (D) HepG2 cells were transfected as indicated. Two
cells were harvested, protein extracted and analyzed by a Western-blot.
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showing a correlation between the reduction in HBV Core protein
and PGC-1a level, we asked whether curcumin suppresses HBV
expression through inhibition of PGC-1a. For this, we employed
the HBV-Luc construct in which the luciferase ORF is cloned down-
stream to HBV enhancer II and to the core promoter (Fig. 2A, upper
panel) [7]. As expected, over-expression of PGC-1a in HBV-Luc
transfected HepG2 cells resulted in a signiﬁcant induction of HBV
transcription as reﬂected by increased luciferase activity. Notably,
whereas curcumin treatment resulted in a modest but still a signif-
icant decrease in HBV-Luc activity under basal conditions in which
PGC-1a level is low, it largely abrogated HBV-Luc induction upon
PGC-1a over-expression (Fig. 2A, lower panel). These results sug-
gest that curcumin suppresses HBV through inhibition of PGC-1a.
Next, we analyzed both HBV mRNA and HBV Core protein levels
under basal conditions and upon PGC-1a over-expression. As ex-
pected, and consistent with the luciferase experiment results,
PGC-1a over-expression resulted in up-regulation of HBV expres-
sion at both the mRNA (Fig. 2B) and at the protein (Fig. 2C) levels.
This induction was completely abrogated upon curcumin treat-
ment and was associated with a sharp decrease in PGC-1a protein
level (Fig. 2C).
Hepatic PGC-1a is robustly induced upon starvation [6]. To
investigate the inhibitory effect of curcumin on the endogenous
PGC-1a level and on HBV expression under conditions mimickingFig. 3. PGC-1a protein is degraded by curcumin. (A) (Left panel) HEK293 cells were trans
untreated or treated with increasing amounts of curcumin (20 and 50 lM) for 4 h after
panel) the same experiment protocol, this time RNA was extracted and analyzed by semi-
were either pre-treated with curcumin (50 lM for 4 h) or left untreated, after which 60 l
extracted and analyzed by a Western-blot for PGC-1a protein level. A representative blot
(100 nM). Four hours after treatment, curcumin (100 lM) was added to the medium for
extracted and subjected to RT-PCR analysis. The resulting cDNA was further ampliﬁed
mRNA. The results are the average of three independent experiments ( indicates P = 0.starvation, HBV-transfected HepG2 cells were pre-treated with for-
skolin and were subsequently treated with curcumin. As shown in
Fig. 2D, both PGC-1a and HBV Core protein levels were induced
upon forskolin treatment, an induction largely abrogated by curcu-
min treatment. Notably, the level of a control GFP protein re-
mained unchanged, ruling out a non-speciﬁc degradation or
translational inhibition effect. Noteworthy is the observation that
even under basal conditions curcumin treatment suppressed HBV
expression, although to a much lower extent (Fig. 2A–D). This
modest effect correlates well with the low level of hepatic PGC-
1a under basal conditions (Fig. 2C and D) in which the gluconeo-
genesis cascade is not activated.
3.2.1. Curcumin inhibition of PGC-1a is at the protein level
We next investigated the mechanism by which curcumin inhib-
its PGC-1a. HEK293 cells were transfected with a PGC-1a expres-
sion plasmid and were subsequently treated with increasing
amounts of curcumin. A co-transfected GFP expression plasmid
was used as a control. A Western-blot analysis revealed that
whereas GFP protein level remained stable, curcumin treatment
resulted in a signiﬁcant reduction in PGC-1a protein level in a
dose-dependent manner (Fig. 3A left panel). Curcumin effect on
PGC-1a is at the protein level, since no change in PGC-1amRNA le-
vel was detected upon curcumin treatment (Fig. 3A right panel).
Based on its predicted intrinsically disordered structure (unpub-fected with the indicated plasmids. Two days after transfection cells were either left
which cells were harvested, protein extracted and analyzed by western blot. (Right
quantitative RT-PCR. (B). HepG2 cells transfected with a PGC-1a expression plasmid
M of cyclohexamide was added for the indicated times. Cells were harvested, protein
is shown. (C). HepG2 cells were treated with forskolin (10 lM) and dexamethasone
additional 4 h. Eight hours after treatment initiation all cells were harvested, RNA
using real-time PCR with the indicated primers. Results were normalized to actin
006, calculated by student’s t-test).
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curcumin-induced protein degradation, as was recently shown
with p53 [16]. Therefore, we further investigated the effect of cur-
cumin on PGC-1a protein stability. For this, cells were transfected
with a PGC-1a expression plasmid, and were subsequently either
treated with curcumin or left untreated. As shown in Fig. 3B, fol-
lowing treatment with the translation inhibitor cyclohexamide
PGC-1a protein level decreased much more rapidly in curcumin
pre-treated cells as compared to non-treated cells, indicating that
curcumin treatment results in a signiﬁcant shortening of PGC-1a
protein half-life. These results strongly suggest that curcumin en-
hances PGC-1a protein degradation.
Next, we asked whether curcumin-induced PGC-1a protein
degradation also translates to a decrease in the expression of the
‘‘classical” PGC-1a target genes. For this, we pre-treated HepG2
cells with dexamethasone and forskolin, two known inducers of
PGC-1a in the liver that simulate a starvation state [6,7], and sub-
sequently treated those cells with curcumin. We analyzed the
mRNA level of the key gluconeogenesis gene G6Pase, a well-known
target of PGC-1a coactivation [6,22]. As expected, the mRNA levels
of both PGC-1a and G6Pase were signiﬁcantly induced by the com-Fig. 4. Curcumin as an additive host-directed anti-HBV therapy. (A) HepG2215 cells
were left either untreated or alternatively treated for 4 h with either Lamivudine
(1 mM), curcumin (150 lM) or the combination of both. Four hour after treatment
initiation cells were harvested and analyzed for HBV mRNA level using quantitative
RT-PCR. Results are presented after normalization to Hypoxanthine-guanine
phosphoribosyltransferase 1 (HPRT1) level as a mean ± S.D. of three experiments,
each performed in triplicates. The P value was calculated using a standard student t-
test. (B) A schematic presentation of HBV life cycle and the targets for conventional
anti-viral (i.e. nucleotide/nucleoside analogues) and the potential host-directed
curcumin therapy.bination of dexamethasone and forskolin treatment. However,
whereas PGC-1a mRNA level remained unchanged upon curcumin
treatment, the mRNA level of its target gene G6Pase was signiﬁ-
cantly reduced (Fig. 3C), suggesting that curcumin inhibits PGC-
1a at the protein level and that this inhibition results in a reduced
expression of its target genes.
3.3. Curcumin and the reverse-transcriptase inhibitor, Lamivudine,
synergistically suppress HBV expression
So far our results indicate that curcumin inhibits HBV through
promoting the degradation of its coactivator PGC-1a. We next
asked whether curcumin treatment could complement the anti-
viral activity of the nucleotide/nucleoside analogues, which are
considered as the gold standard for anti-HBV therapy. For this,
HBV expressing HepG2215 cells were treated with either Lamivu-
dine alone, curcumin alone or with the combination of both. As
shown in Fig. 4A, a 4 h treatment with either Lamivudine or curcu-
min resulted in a signiﬁcant suppression of HBV transcription by
35% and 62%, respectively. However, the combination of both
treatments resulted in an enhanced suppression of HBV expression
by up to 75%, as compared to non-treated cells. These results sug-
gest that curcumin may work synergistically with the current anti-
HBV nucleotide/nucleoside analogous, and that this combination
may result in a better suppression of HBV.
Taken together, in this study we show that PGC-1a protein is
readily degraded by the natural phenolic compound curcumin.
Mechanistically, we show that curcumin promotes the degradation
of PGC-1a protein and signiﬁcantly shortens its half-life (Fig. 3).
We speculate that as a short-lived regulatory protein with
predicted intrinsically disordered structure (unpublished data),
PGC-1a joins a growing group of proteins called IDPs (intrinsically
disordered proteins) that are rendered to degradation upon curcu-
min treatment [16,18,23]. However, although our study clearly
shows that curcumin promotes the degradation of PGC-1a, the ex-
act molecular pathway of this degradation is a subject for further
studies.
Taking advantage of the dependency of HBV on its coactivator
PGC-1a [7], we show that inhibition of PGC-1a by curcumin treat-
ment results in a signiﬁcant suppression of HBV gene expression
and replication markers. Indeed, the inhibitory effect of curcumin
on HBV expression is seen mainly under conditions in which hepa-
tic PGC-1a is over-expressed or induced, such as upon forskolin
treatment mimicking starvation. A much more modest effect,
although still substantial, is seen under basal conditions in which
hepatic PGC-1a levels is relatively low.
Thus, this study joins previous works and provides additional
evidence for the potential importance of nutrition among HBV-in-
fected patients [7,9]. In addition, as a ‘‘metabolovirus” that is pro-
foundly affected by nutritional cues and by hepatic metabolic
pathways [7,9], HBV is potentially susceptible to manipulations
of key molecular players in hepatic metabolic processes such as
gluconeogenesis.
Therefore, we suggest curcumin as a potential host-directed
therapy that may complement the current nucleotide/nucleoside
analogues that directly suppress HBV replication in a virus-speciﬁc
manner (Fig. 4B). As shown experimentally in this study, this com-
bination therapy synergistically suppresses HBV (Fig. 4A). Further-
more, the addition of curcumin to the standard treatment of
nucleotide/nucleoside analogues may minimize the risk of viral
ﬂare-ups under physiological conditions, such as during a short-
term starvation, in which hepatic PGC-1a is induced to coactivate
HBV transcription [7].
Obviously, some major obstacles have to be overcome prior to
the clinical use of curcumin as an anti-HBV drug in humans. First,
whereas host-directed anti-viral therapy has the advantage of
2490 M. Mouler Rechtman et al. / FEBS Letters 584 (2010) 2485–2490avoiding viral-resistance, it carries a substantial risk for unwanted
adverse effects. Accordingly, targeting a cellular coactivator in-
volved in metabolic and energy-related processes such as PGC-1a
[5,6] might result in clinically signiﬁcant adverse outcomes. In-
deed, following curcumin treatment a modest but still signiﬁcant
down-regulation of the key gluconeogenic enzyme G6Pase was ob-
served (Fig. 3C). Therefore, further studies in animals and humans
should be carried out to adjust curcumin dosages that are mini-
mally toxic on the one hand, but still result in a substantial impair-
ment of HBV gene expression and replication on the other hand.
Second, the clinical use of curcumin is hampered by its low sol-
ubility in water, its short half-life and its low bioavailability follow-
ing oral administration [24,25]. Therefore, the reduction in HBV
expression observed in our in vitro studies might be insufﬁcient
in vivo in terms of efﬁcient viral suppression. This obstacle can
be overcome by adopting one of the emerging techniques to in-
crease curcumin bioavailability, such as its oral co-administration
with the alkaloid piperine [26], its liposomal encapsulation for
intravenous administration [27] or using curcumin nanoparticles
that render curcumin completely dispersible in aqueous media
[28]. However, although the feasibility of these techniques in the
context of curcumin-induced HBV inhibition is a subject of further
studies, it holds promise for future use of the ‘‘golden spice” curcu-
min as an efﬁcient anti-HBV therapy that may replace, or at least
complement the ‘‘conventional” anti-viral drugs.
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